Colgate-Palmolive Co (CL)
Fair ValueFundamental
55
मूल्य
$85.32
मार्केट कैप
$68.97B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals. It also offers pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand; and a fresh pet food sold to pet specialty and other retailers in Australia under Prime100 brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
P&G sells to the same supermarket shoppers in nearly every Colgate category, with Crest and Oral-B against Colgate toothpaste and toothbrushes, Olay and Old Spice against Palmolive and Softsoap, and Dawn and Tide against Colgate's home-care lines.
Church & Dwight targets the same US household shopper with TheraBreath mouthwash and Arm & Hammer toothpaste against Colgate's oral care, and with Arm & Hammer and OxiClean against its cleaning brands.
Unilever fights Colgate for the same shelf space in oral care (Closeup, Pepsodent) and personal care (Dove, Lifebuoy), above all in the emerging markets that generate a large share of Colgate's sales.
Haleon is the main rival in premium therapeutic oral care, where Sensodyne, Parodontax and Polident compete directly with Colgate Sensitive, Colgate Total and Colgate's denture-care products, often on pharmacist and dentist recommendation.
Through Purina and Purina Pro Plan Veterinary Diets, Nestlé is the largest player in the pet food aisles and veterinary clinics where Colgate's Hill's Science Diet and Prescription Diet earn roughly a quarter of group sales.
Reckitt competes for the same home-care and hygiene budget, with Lysol, Finish and Air Wick facing Colgate's Ajax, Fabuloso, Axion and Suavitel across the US, Europe and Latin America.
बैलेंस शीट और तरलता
राजस्व
$21.05B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$2.04B
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$3.63B
कुल इक्विटी
$54M
कुल देनदारियाँ
$15.96B
Current Ratio
1.03
Interest Coverage
12.32
Debt/EBITDA
1.99
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$71.98
वर्तमान मूल्य
$85.32
Margin of Safety
-18.5%
Fair Value सीमा
$46.79 - $97.17
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
33.72
ROE
3948.1%
P/B Ratio
288.20
P/FCF
17.63
Gross Margin
60.4%
ROIC
23.2%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
23.2%
WACC
7.5%
ROIC − WACC
+15.8 pp
ROIC पूंजी की लागत से अधिक है — कंपनी शेयरधारकों के लिए मूल्य सृजित कर रही है।
Fundamental विश्लेषण मानदंड
पास (14)
- ROIC 23.2%
- Gross Margin 60.4%
- P/FCF 17.63
- Operating Margin 14.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 631.1%
- Analyst Consensus 65% Buy
- Earnings Quality (OCF/NI) 2.19
- Share Dilution -1.5%
फेल (12)
- EPS shows upward trend
- EPS CAGR -1.08%
- Price CAGR 2.87%
- P/B Ratio 288.20
- Debt/Equity ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 4.3%
- Earnings Surprise avg 0.4%
- Net Margin Trend 9.7% vs 14.5%
- Piotroski F-Score 4/9
अनुपलब्ध (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Noel R. Wallace | Chairman, CEO & President | 61 |
| Mr. Stanley J. Sutula III | Chief Financial Officer | 59 |
| Mr. Panagiotis Tsourapas | COO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | 60 |
| Mr. Shane Grant | Chief Operating Officer of Americas | 50 |
| Mr. Stephan Habif | Chief Technology Officer | - |
| Mr. David Foster | Chief Information Officer | - |
| Mr. John Faucher | Chief Investor Relations Officer and Executive VP of M&A | - |
| Ms. Betsy Fishbone | EVP, Chief Legal Officer & Secretary | - |
| Mr. Eutychus Karuru | Executive Vice President of Internal Audit & Compliance | - |
| Mr. Dana Bolden | Chief Communications Officer | 57 |
Audit जोखिम
3
बोर्ड जोखिम
5
मुआवजा जोखिम
4
शेयरधारक अधिकार जोखिम
2
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-23
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-07-31
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-07-31
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for CL, sourced from Markets Gazette.